NVO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today, Novo Nordisk A/S's share price is $47.62. Novo Nordisk A/S's Book Value per Share for the quarter that ended in Jun. 2016 was $2.53. Hence, Novo Nordisk A/S's P/B Ratio of today is 18.84.
During the past 13 years, Novo Nordisk A/S's highest P/B Ratio was 31.90. The lowest was 3.66. And the median was 8.27.
During the past 12 months, Novo Nordisk A/S's average Book Value Per Share Growth Rate was 11.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 1.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 3.10% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 7.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Novo Nordisk A/S was 17.70% per year. The lowest was -2.30% per year. And the median was 7.60% per year.
Novo Nordisk A/S's P/B ratio for today is calculated as follows:
|P/B Ratio||=||Share Price||/||Book Value per Share (Q: Jun. 2016)|
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book Ratio. The difference between Price-to-Tangible-Book Ratio and Price-to-Book Ratio is that book value other than intangibles are used in the calculation.
Unlike valuation ratios relative to the earning power such as P/E ratio, P/S ratio or Price-to-Free-Cash-Flow ratio, the Price-to-Book Ratio measures the valuation of the stock relative to the underlying asset of the company.
The Price-to-Book Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Novo Nordisk A/S Annual Data
Novo Nordisk A/S Quarterly Data
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.